Evidence map›Paper›PMID 41171531›Full record

ReviewGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026

Metabolic reprogramming as a key regulator in Helicobacter pylori-infected gastric cancer.

Ruofan Cao, Feifei Zhou, Cuiyu Zhu, Hongwei Xu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Rethinking Oxidative Stress inLife (Basel, Switzerland) · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ruofan Cao *Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, People's Republic of China.
Feifei Zhou *Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, People's Republic of China.
Cuiyu ZhuDepartment of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, People's Republic of China.
Hongwei XuDepartment of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, People's Republic of China. xuhongwei@sdfmu.edu.cn.ORCID 0000-0001-8118-5307

Funding

National Natural Science Foundation of China No. 82170650Natural Science Foundation of Shandong Province No. ZR2024QH029
6 · The paper itself

Abstract

Helicobacter pylori (H. pylori) infection is a recognized risk factor for gastric cancer (GC), which is the leading cause of cancer-related deaths worldwide. As a Class I carcinogen, H. pylori plays a central role in the occurrence and development of GC. Recent studies have highlighted the critical role of metabolic reprogramming inthe gastric cancer, and H. pylori infection has been shown to significantly alter metabolic pathways in gastric cancer. This review explores the mechanisms by which H. pylori infection drives metabolic changes in GC, particularly in glycolysis, lipid metabolism, and amino acid metabolism. By altering these metabolisms, H. pylori enhances the survival, proliferation, and metastasis of tumor cells, and also promotes immune evasion. Therefore, understanding the ways in which H. pylori-induced metabolic reprogramming of GC cells is essential for identifying new therapeutic targets. By summarizing the latest research progress of these metabolic pathways, new strategies and directions can be provided for gastric cancer treatment.

Indexed as

Helicobacter InfectionsHelicobacter pyloriStomach NeoplasmsGlycolysisHumansLipid MetabolismMetabolic ReprogrammingGastric cancerHelicobacter pyloriMetabolic reprogrammingTherapy

Identifiers

PMID41171531
PMCPMC12830420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.